Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 4/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 2/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | PYGM | P11217 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6387886 | 0.85 | KDR (0.50) | METKDRRAF1AXLGCK | |
| SCHEMBL1137174 | 0.81 | MET (0.48) | METKDRRAF1AXLGCK | |
| SCHEMBL1137326 | 0.81 | MET (0.44) | METKDRRAF1AXLGCK | |
| SCHEMBL400969 | 0.81 | RAF1 (0.47) | METKDRRAF1P2RX3GRM5 | |
| SCHEMBL1137144 | 0.80 | RAF1 (0.40) | METKDRRAF1AXLGCK | |
| SCHEMBL1137088 | 0.80 | NOS3 (0.47) | METGCK | |
| SCHEMBL1137123 | 0.78 | KDR (0.42) | METKDRRAF1AXLP2RX3 | |
| SCHEMBL105733 | 0.78 | MET (0.44) | METKDRRAF1AXLGCK | |
| SCHEMBL29757310 | 0.78 | GCK (0.56) | METKDRRAF1AXLGCK | |
| SCHEMBL1137603 | 0.78 | GSK3A (0.44) | METKDRRAF1AXLGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2879676-B1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2879677-B1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9326975-B2 | Substituted pyrazolone compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-05-03 | — | — | US | disclosed |
| EP-2879676-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2879677-A2 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20150141463-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-05-21 | — | — | US | disclosed |
| US-8975282-B2 | Substituted pyrazolone compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-8969388-B1 | Substituted pyrazolone compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-20150050239-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150037280-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-02-05 | — | — | US | disclosed |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | MATSUSHIMA TOMOHIRO | 2010-03-25 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150037280-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | MKI67, PRKACA, PRKDC | MET 796/4885KDR 598/4885RAF1 10/4885 |
| US-20150141463-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | MKI67, PRKACA, PRKDC | MET 796/4885KDR 598/4885RAF1 10/4885 |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | MET 162/4885KDR 472/4885RAF1 142/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | MET 162/4885KDR 472/4885RAF1 142/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | MET 2/4885KDR 8/4885RAF1 221/4885 |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | HGF, MET, HDGF | MET 2/4885KDR 9/4885RAF1 223/4885 |
| US-20150050239-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | MKI67, PRKACA, PRKDC | MET 796/4885KDR 598/4885RAF1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.